Dermatología en Costa Rica

Tuesday, October 20, 2020

Secukinumab reduce ACE 2

Journal Scan / Research · October 19, 2020

Secukinumab and Expression of ACE2 in Affected Skin of Patients With Psoriasis

Journal of Allergy and Clinical Immunology

TAKE-HOME MESSAGE


Abstract 

Secukinumab reduced the inflammation and the expression of ACE2, which encodes the SARS-CoV-2 receptor, in plaques of patients with psoriasis. Reductions in ACE2 expression with secukinumab significantly correlated with reductions in disease activity.

Journal of Allergy and Clinical Immunology
Secukinumab Lowers Expression of ACE2 in Affected Skin of Patients With Psoriasis
J. Allergy Clin. Immunol 2020 Sep 28;[EPub Ahead of Print], JG Krueger, DF Murrell, S Garcet, K Navrazhina, PC Lee, E Muscianisi, A Blauvelt

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.

0 Comments:

Post a Comment

Subscribe to Post Comments [Atom]



<< Home